{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:24:24Z","timestamp":1784690664052,"version":"3.55.0"},"reference-count":54,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T00:00:00Z","timestamp":1440028800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epidemiol Psychiatr Sci"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:p>To date, antipsychotics remain the mainstay of treatment for schizophrenia and related disorders although other psychotropic medications and non-pharmaceutical interventions have been used adjunctively in some patients and settings. Regular surveys on access to and prescription patterns of psychotropic medications in clinical practice are an important and efficient way of examining the use and time trends of treatments in a given population and region. Unlike developed Western countries, Asian countries have not fully undergone deinstitutionalisation of the severely and chronically mentally ill, and community-based mental health services are still under-developed. As a result, a large number of psychiatric patients still receive treatments in psychiatric hospitals. Moreover, there have been very limited studies examining access to and prescription patterns of psychotropic medications for schizophrenia patients in Asian countries. In this paper, we focus on the only international project on the use of psychotropic medications in schizophrenia patients<jats:italic>in selected East and Southeast Asian countries\/territories<\/jats:italic>summarising its major findings. Most of the first- and second-generation antipsychotics (FGAs and SGAs) are available in Asian countries, but the access to psychotropic medications is largely affected by socio-cultural and historical contexts, health insurance schemes, health care policy, medication cost and consumers\u2019 preference across different countries\/territories. Overall, the proportional use of FGAs, high dose antipsychotic treatment and antipsychotic polypharmacy have decreased, while the use of SGAs and antidepressants have increased and the utilisation of benzodiazepines and mood stabilisers has remained relatively stable over time. However, within these general trends, there is great inter-country variation regarding the psychotropic prescribing patterns and trends in Asian schizophrenia patients that also seems to differ from data in many Western countries.<\/jats:p>","DOI":"10.1017\/s2045796015000694","type":"journal-article","created":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T09:47:24Z","timestamp":1440064044000},"page":"9-17","source":"Crossref","is-referenced-by-count":23,"title":["Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia"],"prefix":"10.1017","volume":"25","author":[{"given":"Y.-T.","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. S.","family":"Ungvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. F. K.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Shinfuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2015,8,20]]},"reference":[{"key":"S2045796015000694_ref13","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbn018"},{"key":"S2045796015000694_ref52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1758-5872.2012.00231.x"},{"key":"S2045796015000694_ref43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.1997.tb03204.x"},{"key":"S2045796015000694_ref17","first-page":"1227","article-title":"Utilization of levomepromazine in Japan \u2013 Its role as an antipsychotic in psychiatric pharmacotherapy (In Japanese)","volume":"8","author":"Fujii","year":"2005","journal-title":"Rinsyo Seisin Yakuri"},{"key":"S2045796015000694_ref49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1055\/s-0031-1301292","article-title":"Adjunctive mood stabilizer and benzodiazepine use in older Asian patients with schizophrenia, 2001\u20132009","volume":"45","author":"Xiang","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"S2045796015000694_ref35","first-page":"CD005581","article-title":"Antidepressants for the negative symptoms of schizophrenia","volume":"3","author":"Rummel","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"S2045796015000694_ref20","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200620040-00003"},{"key":"S2045796015000694_ref19","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.683523"},{"key":"S2045796015000694_ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.03.018"},{"key":"S2045796015000694_ref5","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e31815ac4e5"},{"key":"S2045796015000694_ref14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.31887\/DCNS.2011.13.2\/ccorrell","article-title":"Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives","volume":"13","author":"Correll","year":"2011","journal-title":"Dialogues in Clinical NeuroSciences"},{"key":"S2045796015000694_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijlp.2005.08.004"},{"key":"S2045796015000694_ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2004.01194.x"},{"key":"S2045796015000694_ref2","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1176\/ajp.144.11.1494","article-title":"Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan","volume":"144","author":"Binder","year":"1987","journal-title":"American Journal of Psychiatry"},{"key":"S2045796015000694_ref4","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp116"},{"key":"S2045796015000694_ref46","volume-title":"Mental Health Atlas \u2013 2011 Country Profiles","year":"2011"},{"key":"S2045796015000694_ref50","doi-asserted-by":"publisher","DOI":"10.1177\/0004867412453625"},{"key":"S2045796015000694_ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.10.015"},{"key":"S2045796015000694_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)90206-8"},{"key":"S2045796015000694_ref44","doi-asserted-by":"publisher","DOI":"10.3758\/BF03333140"},{"key":"S2045796015000694_ref47","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-992143"},{"key":"S2045796015000694_ref54","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145712001277"},{"key":"S2045796015000694_ref53","first-page":"1000","article-title":"The effect of locally manufactured aripiprazole in treatment of first episode schizophrenia (in Chinese)","volume":"22","author":"Yin","year":"2005","journal-title":"Journal of Clinical Research"},{"key":"S2045796015000694_ref48","doi-asserted-by":"publisher","DOI":"10.1002\/hup.821"},{"key":"S2045796015000694_ref30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01953.x"},{"key":"S2045796015000694_ref37","doi-asserted-by":"publisher","DOI":"10.1080\/09540260802397560"},{"key":"S2045796015000694_ref28","first-page":"216","article-title":"A comparative study of locally manufactured intramuscular ziprasidone and haloperidol in treating acute atitation in schizophrenia (in Chinese)","volume":"39","author":"Li","year":"2006","journal-title":"Chinese Journal of Psychiatry"},{"key":"S2045796015000694_ref33","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528030-00002"},{"key":"S2045796015000694_ref10","doi-asserted-by":"publisher","DOI":"10.1177\/875512259501100210"},{"key":"S2045796015000694_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2009.09.001"},{"key":"S2045796015000694_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.01.008"},{"key":"S2045796015000694_ref6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1614.2002.01037.x"},{"key":"S2045796015000694_ref34","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a007025"},{"key":"S2045796015000694_ref1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbn030"},{"key":"S2045796015000694_ref11","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.51.5.634"},{"key":"S2045796015000694_ref41","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.1532"},{"key":"S2045796015000694_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.11.030"},{"key":"S2045796015000694_ref42","doi-asserted-by":"publisher","DOI":"10.1017\/S146114571000163X"},{"key":"S2045796015000694_ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"S2045796015000694_ref32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003150"},{"key":"S2045796015000694_ref8","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X187883"},{"key":"S2045796015000694_ref38","unstructured":"Si TM (2014). The Third Survey of Prescription Pattern of Psychotropic Drugs in China: Schizophrenia Patients Prescription Status. In The Chinese Society of Neuroscience & Psychiatry Annual Meeting, Nanchang."},{"key":"S2045796015000694_ref51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-0031-1286345","article-title":"Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001\u20132009)","volume":"45","author":"Xiang","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"S2045796015000694_ref16","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10060908"},{"key":"S2045796015000694_ref7","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2006.57.8.1094"},{"key":"S2045796015000694_ref26","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp130"},{"key":"S2045796015000694_ref29","first-page":"289","article-title":"The comparison of use of antipsychotics in first-episode patients with schizophrenia (in Chinese)","volume":"15","author":"Liu","year":"2003","journal-title":"Medical journal of Chinese people Health"},{"key":"S2045796015000694_ref15","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108100777"},{"key":"S2045796015000694_ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(01)00279-2"},{"key":"S2045796015000694_ref45","volume-title":"Guidelines for ATC Index with DDDs","year":"2002"},{"key":"S2045796015000694_ref39","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.109.067710"},{"key":"S2045796015000694_ref25","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"S2045796015000694_ref36","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0417"},{"key":"S2045796015000694_ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0719-7"}],"container-title":["Epidemiology and Psychiatric Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2045796015000694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T18:10:55Z","timestamp":1653070255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2045796015000694\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,20]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S2045796015000694"],"URL":"https:\/\/doi.org\/10.1017\/s2045796015000694","relation":{},"ISSN":["2045-7960","2045-7979"],"issn-type":[{"value":"2045-7960","type":"print"},{"value":"2045-7979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,20]]}}}